INVX Innovex International, Inc. Insider Trading

Director-linked INNOVEX CO-INVEST FUND sells 6,612,500 shares (97.0% of holdings) for $162,609,971.25 at $24.59

INNOVEX CO-INVEST FUND, L.P., a Director at Innovex International, Inc., executed 6 separate sales totaling 6,612,500 shares for $162,609,971.25 on 2026-02-27, reducing its holdings from 6,819,740 shares to 207,240 shares. This near-complete exit occurs at $24.59 per share while the stock currently trades at $26.35, suggesting the sales were executed below present market levels. The company shows strong fundamentals with $240.0M quarterly revenue, $39.2M net income, and 48.0% annual revenue growth, yet the fund's decision to liquidate 97.0% of its position warrants scrutiny of the fund's capital allocation priorities and any broader strategic or liquidity considerations driving this substantial reduction.

Amberjack Capital Partners liquidates 6,612,500 shares (97.0% of holding) for $162,609,971.25 at $24.59

Amberjack Capital Partners, as a Director, executed 6 separate sales on 2026-02-27 totaling 6,612,500 shares for $162,609,971.25, reducing its stake from 6,819,740 shares to 207,240 shares—a near-complete exit representing 97.0% of pre-transaction holdings. The sales occurred at $24.59 per share while the stock currently trades at $26.35, meaning the insider sold below recent price levels and the current 52-week range peak of $29.25. This magnitude of stake reduction by a director in a company with $1.8B market cap, $240.0M quarterly revenue, and 48.0% annual growth warrants investor attention to the motivation and timing context underlying such a substantial position unwind.

CEO Anderson Adam sells 18,837 shares of INVX at $28.50; stock near 52-week high ($29.25 current)

Anderson Adam, Chief Executive Officer, sold 18,837 shares at $28.50 on 2026-02-24, reducing his holdings by 3.9% to 466,744 shares. The transaction price of $28.50 is within 2.6% of the current price of $29.25, which sits at the 52-week high, and the stock has appreciated 14.0% over the past 30 days and 30.9% over 90 days. Against this backdrop of strong recent price momentum, the CEO's open-market sale merits investor attention as a directional signal on valuation perception. The company's fundamentals remain robust—$240.0M in quarterly revenue with 48.0% annual growth and a $2.0B market capitalization—though the elevated P/E of 45.70 reflects current market expectations; this sale does not necessarily imply operational concern but rather occurs at a price point at or very near peak historical valuation.

CFO Reed Kendal purchases 3.8K shares of INVX for $50.0K at $13.28 amid 26.3% decline from 52-week high; stock down 20.4% in 30 days

Reed Kendal, Chief Financial Officer of Innovex International, acquired 3,765 shares at $13.28 on 2024-12-13, raising his holdings from 182,467 to 186,232 shares. The transaction occurred while the stock trades at $12.95, representing a 26.3% decline from the 52-week high of $17.58 and reflecting significant recent weakness (down 20.4% over 30 days and 19.4% over 90 days). The company's fundamentals remain solid with $151.8M in quarterly revenue, $82.6M in net income, and 17.1% annual revenue growth, supported by an attractive P/E of 7.90. The insider's purchase during a period of material price depreciation occurs against a backdrop of strong operational performance, presenting a factual data point for investors to assess in relation to the company's near-term momentum and valuation posture.